Site-Central Discordance in Oncology Trial Imaging

Gregory Goldmacher, MD, PhD, MBA

Chief Scientific and Medical Officer, Perceptive Imaging

Dr. Goldmacher has two decades of experience across clinical development, medical imaging, and data science. During 11 years at Merck, he led clinical imaging and pathology strategy, supported 300+ trials and 50+ regulatory approvals, and advanced the use of AI and analytics in clinical research. Earlier he served as Head of Oncology Imaging at ICON Clinical Research, overseeing imaging across 100+ trials.
He has authored numerous publications, including “Setting the standard: Empirical Benchmarks for Case-level Site–central Discordance in Radiographic Endpoints in Oncology Clinical Trials” (Contemporary Clinical Trials Communications, Sep. 2026) and actively contributes to cross-industry scientific and standards initiatives.

Peter Eggleton, MD, FPPM 

Vice President, Scientific and Medical Services, Perceptive Imaging

Dr. Eggleton holds dual specialist certifications in diagnostic radiology and pharmaceutical medicine and has 35+ years of experience in pharmaceutical clinical development, with a particular focus on solid tumor oncology and neurology. He is thought to be the only radiologist who has led a therapeutic blockbuster to global regulatory success. He specializes in applying imaging science to study and project design to maximize opportunities for success and has authored numerous publications on both imaging science and general oncology clinical research. For many years, he served as Principal Expert for Diagnostic Radiology and Pharmaceutical Development at Merck KGaA in Darmstadt, Germany.

Manuela Lesch, RT

Senior Scientific Director, Perceptive Imaging

Manuela Lesch has more than 20 years of experience in clinical trial imaging, with expertise in oncology and neuro-oncology. Since joining Perceptive in 2004, she has specialized in imaging strategies for complex clinical trials, including solid tumors, primary brain tumors, and brain metastases. As Scientific Operations Lead for Solid Tumors, she provides scientific leadership across study design, imaging endpoints, independent review, and assessment criteria. She works closely with sponsors to develop fit-for-purpose imaging strategies and contributes to scientific strategy, business development, and the advancement of imaging approaches for oncology clinical research.